IO BIOTECH INC. - COM

IO Biotech to Present at Jefferies Global Healthcare Conference

23 May 2024 07:30:00 By Nasdaq GlobeNewswire

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

14 May 2024 06:55:00 By Nasdaq GlobeNewswire

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 15:30:00 By Nasdaq GlobeNewswire

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

15 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

09 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

05 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

06 Mar 2024 15:11:01 By Nasdaq GlobeNewswire

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

05 Mar 2024 15:40:01 By Nasdaq GlobeNewswire

IO Biotech to Present at 44th Annual Cowen Health Care Conference

26 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

21 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces 2023 Third Quarter Results

13 Nov 2023 07:12:16 By Nasdaq GlobeNewswire

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

13 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

10 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

08 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

01 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress

23 Oct 2023 00:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

12 Sep 2023 07:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

06 Sep 2023 07:35:00 By Nasdaq GlobeNewswire

IO Biotech Announces 2023 Second Quarter Results

11 Aug 2023 07:30:00 By Nasdaq GlobeNewswire